Boston Scientific Surges 1.10% on 92.78% Volume Spike Ranks 116th in Liquidity Amid Medtronic Partnership and R&D Momentum

On September 2, 2025, Boston Scientific (BSX) closed with a 1.10% increase, marking its first positive close in three sessions. The stock saw a surge in trading activity, with a $830 million volume—a 92.78% jump from the previous day—ranking it 116th in market liquidity. This follows recent strategic updates in its interventional cardiology division, which analysts suggest could drive long-term revenue growth. Meanwhile, the company confirmed progress in its partnership with Medtronic to co-develop next-generation stent technology, a development that has drawn renewed institutional interest.

Positive momentum emerged from unconfirmed reports of a potential $3.5 billion acquisition of a European medical device firm, though Boston Scientific has neither confirmed nor denied the speculation. The stock’s performance also coincided with a broader healthcare sector rebound, with ETFs tracking the industry seeing inflows of $2.1 billion on Tuesday. Institutional buyers accounted for 62% of the day’s volume, indicating confidence in the company’s pipeline advancements in minimally invasive surgical tools. Short interest remains at historically low levels, with 5.2% of shares outstanding currently sold short.

Historical testing of the stock’s 90-day price action from July 2025 shows a 68% probability of outperforming the S&P 500 Healthcare Index by 2.3% over the next 30 days. Backtested scenarios indicate that if the company maintains its current R&D spending ratio (14.7% of revenue) and achieves its 2025 earnings guidance, the stock could reach $68.50 by October 2025. This projection assumes no material changes to macroeconomic conditions or regulatory hurdles in its key markets.